Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting 9-12 November 2016, Lisbon, Portugal

Soft Tissue Sarcoma: What is best practice?

Chaired by Alessandro Gronchi
Thursday 10th November 2016, Lisbon

This event was accredited for CME by the EACCME®

Scientific summary

A documented account of the symposium presentations, associated discussions and video highlights.

Download here:

CTOS_SS front cover

  • Chair: Alessandro Gronchi
    Fondazione IRCCS Istituto Nazionale dei Tumori (National Cancer Institute) Milan, Italy
    Welcome and introduction
    Gronchi

    Angelo Paolo Dei Tos
    Treviso General Hospital, Italy
    Translating the biology of soft tissue sarcoma (STS) into therapy
    Angelo Paolo Dei Tos

    Peter Hohenberger
    University of Heidelberg, Germany
    Optimal care in the multidisciplinary setting
    ARTIS-Uli Deck// 26.02.2015 - 28.02.2015 Sarkomkonferenz 2015 www.artis-foto.de -ARTIS-ULI DECK Werrabronner Strasse 19 76229 KARLSRUHE TEL: 0049 (0) 721-84 38 77 FAX: 0049 (0) 721 84 38 93 Mobil: 0049 (0) 172 7292636 E-Mail: deck@artis-foto.de

    Robin Jones
    The Royal Marsden Hospital, London, UK
    Current perspectives on the treatment of patients with advanced-STS
    RLJ Bio

    Alessandro Gronchi
    Closing remarks

  • 18:30-19:45, Opala Rooms I, II and III, 1st Floor, Corinthia Hotel Lisbon

    • 18:30 – 18:35 Welcome and introduction – Alessandro Gronchi
    • 18:35 – 18:55 Translating the biology of STS into therapy – Angelo Paolo Dei Tos
    • 18:55 – 19:20 Optimal care in the multidisciplinary setting – Peter Hohenberger
    • 19:20 – 19:40 Current perspectives on the treatment of patients with advanced-STS – Robin Jones
    • 19:40 – 19:45 Closing remarks – Alessandro Gronchi

     

    A buffet reception will be provided from 18:00 for attendees of this symposium, in Esmerelda Rooms I and II adjacent to Opala

     

  • After attending this symposium, learners will be able to:

    • Describe the biological pathways involved in STS and discuss their implications for the pathology of STS
    • Assess the new treatment and diagnosis paradigms for advanced-STS and explain how to best apply them to their daily practice
    • Explain the current best practice for providing treatment for STS within the context of the multidisciplinary team

  • Dear Colleagues,

    Welcome to Lisbon and thank you for attending this satellite symposium entitled ‘Soft Tissue Sarcoma: What is best practice?’ at the Connective Tissue Oncology Society Annual Meeting 2016.

    Lisbon provides a soulful, captivating and picturesque host backdrop for this conference that brings together a unique community of medical professionals from across Europe. The aim of this symposium is to facilitate the management of soft tissue sarcoma, and the implementation of new discoveries in clinical practice. It will also address the challenges facing clinicians in an increasingly complex treatment landscape.

    During the session, the expert Faculty will guide us through this complexity by placing the latest developments in soft tissue sarcoma into the context of treatment. They will also provide their insights into how we can best use these latest developments in sarcoma treatment and how to implement them within a multidisciplinary care team.

    We hope that you find this symposium a valuable educational experience and that it will further your understanding of this evolving field. Accordingly, we aim to provide maximum interaction and discourse between Faculty and audience so that we may work together to optimise patient outcomes.

    Yours faithfully, Alessandro Gronchi

    Gronchi

  • Chair: Dr. Alessandro Gronchi
    Fondazione IRCCS Istituto Nazionale dei Tumori (National Cancer Institute) Milan, Italy
    Gronchi
    Alessandro Gronchi MD received his MD degree from Milan University with honours in 1992 and completed his residency training in General Surgery at the San Raffaele General Hospital, Milan.

    He completed his training with a fellowship in Surgical Oncology at the National Cancer Institute, Milan in 1998 and later joined the faculty at the Department of Surgery at the National Cancer Institute, as attending surgeon in the Sarcoma Service. He has been Chair of the Sarcoma Service at the National Cancer Institute in Milan since 2001 and runs their Sarcoma database, which gathers clinical and biological information on over 8000 patients affected by STS, DF and GIST, treated over the past three decades in Milan.

    As Principal Investigator on several international trials on STS, DF and GIST, Dr Gronchi’s research has focussed on neoadjuvant therapies in extremity and retroperitoneal sarcomas, new targets for specific STS subtypes, different telomere maintenance mechanisms in STS subtypes, genomic characterisation of DF and mechanisms of resistance to therapy in GIST.

    He currently serves as Chairman of the Soft Tissue Sarcoma Committee of the Italian Sarcoma Group (ISG), Chair of the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group and President of the Connective Tissue Oncology Society (CTOS) 2016, member of the Board of Directors of the Italian Society of Surgical Oncology (SICO), the European Society for Medical Oncology (ESMO), the European Society of Surgical Oncology (ESSO), the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO). Dr Gronchi has authored more than 240 scientific publications, serves as Associate Editor of the Sarcoma Journal and was Sarcoma Section Editor of the Annals of Surgical Oncology 2009–2014.

    Angelo Paolo Dei Tos
    Treviso General Hospital, Italy
    Angelo Paolo Dei Tos
    Angelo Paolo Dei Tos, MD, is Professor of Pathology at the University of Padua School of Medicine., Director of the Department of Oncology and Director of Pathology at the General Hospital in Treviso, Italy. He is also a Consultant Pathologist at the Istituto Ortopedico Rizzoli in Bologna.
    Professor Dei Tos is a past Chairman and founder of the Working Group on Soft Tissue Tumour Pathology of the European Society of Pathology (ESP), past President of the International Society of Bone and Soft Tissue Pathology (ISBSTP), panel member for the WHO Working Group for the Classification of Tumours of Soft Tissue and Bone, member of the Board of Directors and Past President of CTOS, member of the Soft Tissue and Bone Group of EORTC, and a faculty member of ESMO.

    Professor Dei Tos is a member of the editorial boards of several scientific journals, including the Journal of Pathology, the American Journal of Clinical Pathology, the Journal of Clinical Pathology, Advances in Anatomic Pathology, Seminars in Diagnostic Pathology, Virchows Archiv, and Surgical Oncology.  He is also co-Editor in chief of the Open Access Journal Clinical Sarcoma Research. He has published more than 250 peer-reviewed articles, mainly focused on soft-tissue and tumour pathology/biology and oncological pathology. His main clinical interest is focused on sarcoma morphologic and molecular diagnosis.

    Peter Hohenberger
    University of Heidelberg, Germany
    ARTIS-Uli Deck// 26.02.2015 - 28.02.2015 Sarkomkonferenz 2015 www.artis-foto.de -ARTIS-ULI DECK Werrabronner Strasse 19 76229 KARLSRUHE TEL: 0049 (0) 721-84 38 77 FAX: 0049 (0) 721 84 38 93 Mobil: 0049 (0) 172 7292636 E-Mail: deck@artis-foto.de
    Peter Hohenberger, MD, is Head of the Division of Surgical Oncology and Thoracic Surgery at the Medical Faculty Mannheim, University of Heidelberg. He is a surgeon in visceral and vascular surgery as well as in thoracic surgery and surgical intensive care. His professional education was received at the University of Erlangen, including training in psychology and pathology. Dr Hohenberger’s surgical qualifications were received at the University of Heidelberg, including a senior position at the Department of Surgery followed by a Professorship on Surgical Oncology at Charité, Berlin.

    Having specialised in the treatment of GIST and sarcoma, he became Chairman of the EORTC Soft Tissue and Bone Sarcoma Group. Having worked with the EORTC (GI, melanoma and STBSG) since the 1980s, he was member of the Protocol Review Committee (PRC) and the Board of EORTC for nine years. He has served on the Faculty of the American Association for Cancer Research (AACR), ASCO, the Federation of European Cancer Societies (FECS) and the ESMO course on Methods of Clinical Cancer Research for seven years and is member to the advisory board of SPAEN (Sarcoma Patients Euronet), Das LEBENSHAUS and SOS-DESMOID. He chairs the German Interdisciplinary Sarcoma Group (GISG) and the Interdisciplinary Working Party on Sarcoma (IAWS) of the German Cancer Society (DKG).

    The Mannheim Sarcoma Centre is a major contributor to multinational randomised studies on the treatment of GIST and sarcoma, hosts the Data Center of GISG and was co-founder of the German Sarcoma Conference. Trial activities also include EU-funded EUROSARC, CONTICANET, MITIGATE and, most recently, as part of a research network pursuing the treatment of imatinib-resistant GIST.

    R
    obin Jones
    The Royal Marsden Hospital, UK
    RLJ Bio
    Robin L Jones BSc, MB, MRCP, MD(Res) is a medical oncologist with a specialist interest in bone and soft tissue sarcomas. He completed a first class honours intercalated BSc and medical degree at Guys’ and St Thomas’ Hospitals (University of London). His medical oncology training was at the Royal Marsden Hospital and his postgraduate research degree (Evaluating potential biomarkers in breast cancer patients treated with neoadjuvant therapy) was at the Institute of Cancer Research.

    Between 2010 and 2014 he led the sarcoma program at the University of Washington and Fred Hutchinson Cancer Research Center in Seattle. Since 2015, he has been head of the Sarcoma Unit at the Royal Marsden Hospital. He has a number of ongoing translational and clinical studies in sarcomas.

  • eacceme-logoThe ‘Soft tissue sarcoma: what is best practice?’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

    The ‘Soft tissue sarcoma: what is best practice?’ is designated for a maximum of (or ‘for up to’) 1 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

    Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

    Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.